Joseph Gathe, MD
Infectious Disease · Houston, TXNPI 1366436263
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $529,451 of the $695,237 with a category attached, or 76.2%. 45 manufacturers reported payments, led by Janssen Products, LP at 49.8% of the total. Among infectious disease clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,505 payments — averaging $461.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Products, LP$346K
- Gilead$205K
- EMD Serono, Inc.$81K
- AbbVie$32K
- La Jolla Pharmaceutical Company$12K
- Tetraphase Pharmaceuticals, Inc.$5K
- plus $14K from 39 others
Across 183 payments — averaging $6802.76 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Beigene, Ltd.$331K
- Gilead$294K
- Janssen Research & Development, LLC$264K
- Theratechnologies Inc.$194K
- AbbVie$94K
- Regeneron$62K
- plus $6K from 1 others
What the payments were for
- Consulting fees$20,4253%
- Speaking & faculty fees$529,45176%
- Travel & lodging$117,13117%
- Food & beverage$27,6664%
- Education$5640%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$695,237 in reported general payments places this provider in the 95th percentile of 576 infectious disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 1,062 | $4,366,661 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 411 | $1,959,059 |
| PrezcobixDarunavir/Cobicistat | 601 | $1,592,281 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 255 | $1,103,264 |
| SerostimSomatropin | 33 | $824,769 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 205 | $760,650 |
| TivicayDolutegravir Sodium | 253 | $722,125 |
| DovatoDolutegravir Sodium/Lamivudine | 186 | $567,751 |
| DescovyEmtricitabine/Tenofov Alafenam | 251 | $562,598 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 98 | $412,677 |
| Egrifta SvTesamorelin Acetate | 44 | $354,293 |
| RukobiaFostemsavir Tromethamine | 45 | $344,637 |
| TrogarzoIbalizumab-Uiyk | 23 | $284,879 |
| IsentressRaltegravir Potassium | 134 | $279,741 |
| JulucaDolutegravir/Rilpivirine | 60 | $208,317 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Genvoya, Descovy, Stribild | $204,712 | $6,240,2491,620 claims |
| Viiv Healthcare CompanyTriumeq, Tivicay, Dovato, Rukobia, Juluca | $2,047 | $2,603,480749 claims |
| Janssen Products, LPSymtuza | $346,284 | $1,959,059411 claims |
| Johnson & JohnsonPrezcobix, Complera | $1,830 | $1,642,277615 claims |
| EMD Serono, Inc.Serostim | $81,162 | $824,76933 claims |
| Theratechnologies Inc.Egrifta Sv, Trogarzo | $3,357 | $639,17267 claims |
| MerckIsentress, Delstrigo, Isentress Hd | $981 | $439,662200 claims |
| Novo NordiskOzempic | $59 | $81,49388 claims |
| Lilly USA, LLCMounjaro | $151 | $62,08248 claims |
| PfizerEliquis, Selzentry | $36 | $45,56852 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $276 | $30,59314 claims |
| AbbVieLinzess | $32,492 | $22,47335 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 576 infectious disease providers in Texas.
Other infectious disease in Houston
- Roy ChemalyHouston$686K
- Ben BarnettHouston$424K
- Amar SafdarHouston$284K
- Luis OstroskyHouston$173K
- Richard HamillHouston$137K
- Karen VigilHouston$91K
- John RexHouston$63K
- Pablo OkhuysenHouston$57K
- Rodrigo HasbunHouston$51K
- Edward SeptimusHouston$50K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.